Inhibitors of Intracellular RyR2 Calcium Release Channels as Therapeutic Agents in Arrhythmogenic Heart Diseases.

Journal

Annual review of pharmacology and toxicology
ISSN: 1545-4304
Titre abrégé: Annu Rev Pharmacol Toxicol
Pays: United States
ID NLM: 7607088

Informations de publication

Date de publication:
07 Oct 2024
Historique:
medline: 7 10 2024
pubmed: 7 10 2024
entrez: 7 10 2024
Statut: aheadofprint

Résumé

Ryanodine receptor type 2 (RyR2) is the principal intracellular calcium release channel in the cardiac sarcoplasmic reticulum (SR). Pathological RyR2 hyperactivity generates arrhythmia risk in genetic and structural heart diseases.

Identifiants

DOI: 10.1146/annurev-pharmtox-061724-080739 PMID: 39374431
pubmed: 39374431
doi: 10.1146/annurev-pharmtox-061724-080739
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Tri Q Do (TQ)

Vanderbilt Center for Arrhythmia Research and Therapeutics, Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA; email: bjorn.knollmann@vanderbilt.edu.

Björn C Knollmann (BC)

Vanderbilt Center for Arrhythmia Research and Therapeutics, Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA; email: bjorn.knollmann@vanderbilt.edu.

Classifications MeSH